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ABSTRACT
Objectives: This study aims primarily to determine
whether whole body MRI (WB-MRI) and Sestamibi
Technetium-99m-bone marrow (MIBI) scans in the
same patients produce the same estimate of disease
load and location, and secondly, to study possible
association between the bone disease detected by
these scans and the effect on disease outcome and
survival. Bone disease occurs in about 90% of multiple
myeloma (MM) patients. There are no data comparing
the new diagnostic modalities with WB-MRI and MIBI
in MM.
Design: A prospective comparative study between
WB-MRI and MIBI scans in assessing bone disease
and outcome of MM.
Participants and methods: Sixty-two consecutive
patients with confirmed MM underwent simultaneous
WB-MRI (both axial T1 and turbo spin echo short tau
inversion recovery (STIR)) and MIBI scans at a single
institution from January 2010 to January 2011, and
their survival status was determined in January 2012.
The median age was 62 years (range 37–88) with a
male-to-female ratio of 33 : 29.
Results: In vertebrae and long bones, MRI scan
detected more disease compared with MIBI scan
(p<0.001) but there was less difference in the skull
(p=0.09). In the ribcage, the MIBI scan detected more
lytic lesions of the ribs compared with MRI scan
(p<0.001). Thirteen of the 62 patients died during the
24-month follow-up. Increased disease detected in all
bones by both scans was associated with increased
mortality risk (MIBI p=0.001; MRI-STIR p=0.044; but
not MRI-T1 p=0.44). In all combined bone groups, the
mean MIBI scan results provided a better prediction of
mortality than MRI scan over the follow-up period
(MRI-T1 vs MIBI p=0.019; MRI-STIR vs MIBI
p=0.047).
Conclusions: Although WB-MRI detected more MM
bone disease, MIBI scan predicted overall disease
outcome and mortality better than MRI scan. Further
studies to define optimum use of these imaging
techniques are warranted.
Trial registration number: The study was registered
prospectively in the Australian and New Zealand
Clinical Trials Registry at http://www.ANZCTR.org.au
under No: ACTRN12609000761268.
INTRODUCTION
Multiple myeloma (MM) is a malignant neo-
plasm of plasma cells resulting in osseous
ARTICLE SUMMARY
Article focus
▪ Bone disease occurs in about 90% of multiple
myeloma (MM) patients.
▪ Among the four available radionuclear imaging
techniques, there are no data comparing whole-
body MRI (WB-MRI) and Sestamibi Technetium-
99m-MIBI bone marrow (MIBI) scan in assessing
bone disease in MM.
▪ Therefore, there is a growing interest in the role
of MIBI scanning in conjunction with WB-MRI in
determining the extent of myeloma bone disease
and the prediction of disease outcome.
Key messages
▪ WB-MRI scan identifies more myeloma bone
disease than the MIBI scan with more sensitivity in
detecting myelomatous deposits in the spine and
to a lesser extent, in the pelvic and long bones.
However, in the ribcage, MIBI scan detected more
disease compared to MRI scan (p<0.001).
▪ A novel finding shows that MIBI scan obtains an
image of all important bone compartments in the
body in one single examination, and is less time
consuming and more comfortable for the patient
than MRI.
▪ MIBI scan was able to predict overall disease
outcome and mortality better than MRI scan.
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destruction.1–3 Most institutions utilise a skeletal survey in
order to radiologically assess MM at diagnosis.3–5
Although skeletal survey was considered for many
decades as a standard radiological technique in the diag-
nosis and staging of myeloma bone disease, it has a high
false-negative rate of between 30% and 70% leading to
underestimation of disease burden.6 7 MRI is currently
used in several contexts in the monitoring of MM with
high sensitivity compared with CT scan in detecting
myeloma bone lesions.5–7 MRI is useful in identifying
MM by its infiltration of normal fat within the bone
marrow.5–8 Marrow infiltration seen on MRI can be used
to assess the tumour burden present at diagnosis.7–9 In
2005, the Durie and Salmon staging system was refined to
include whole body MRI (WB-MRI) where available.10 11
Sestamibi Technetium-99m MIBI bone marrow scan-
ning (MIBI) accurately represents myeloma activity in the
bone marrow with high sensitivity and specificity.12–14
There is also a linear correlation between bone marrow
biopsy results and uptake on MIBI scan.12 However, there
are no available data comparing MRI and MIBI scans in
assessing disease activity and mortality in MM. Currently,
MRI is the imaging modality of choice in staging MM
disease according to the Durie-Salmon-PLUS staging
system.10 Radionuclide imaging offers a potential alterna-
tive or supplement to radiographic detection and assess-
ment of disease activity.11–17 There is scant evidence
comparing MRI and MIBI bone marrow scans in asses-
sing disease activity in MM in a cohort of this size.
Therefore, there is a growing interest and recognition of
the important role of MIBI bone marrow scan in imaging
malignant tumours.
Rationale and aims of the study
Bone disease occurs in about 90% of MM patients.3
There are four available routine radio-nuclear imaging
techniques for the diagnosis of bone disease in MM,
which are plain x-ray, CT, MRI and bone scans.5 11 15
Another technology employing positron emission tom-
ography (PET) is considered mainly for research pur-
poses and is not performed routinely for the diagnosis
of myeloma. Plain radiographs can only demonstrate
lytic bone disease when 30% or above of trabecular
bone has been lost, which represents a late stage of the
disease.15 16 Furthermore, skeletal survey is not sensitive
enough to monitor the responses to therapy.
Technetium-99m bone scanning without sestamibi is
not appropriate for evaluating myeloma bone disease
since bone scans reflect osteoblastic activity and thus,
underestimates the extent of osteolytic lesions character-
istic for myeloma bone disease.12–14 MIBI scanning has
been investigated in myeloma patients because it is con-
centrated in myeloma tissue and thus, was found to be
more sensitive than skeletal survey (77% vs 45%) and
was highly specific for staging myeloma patients.17
MRI has been proven in many studies to be more accur-
ate than plain x-ray or CT scan in detecting myeloma
bone lesions with a higher sensitivity.6–9 Therefore, MRI
is considered to be a useful tool in the prediction of
myeloma disease response; hence, new guidelines have
integrated MRI as part of the staging of myeloma bone
disease.10 11 However, WB-MRI is a potential imaging
method for high-resolution screening of the whole skel-
eton in patients with MM.8
There are little data available regarding this new tech-
nique especially in conjunction with other newly devel-
oped techniques like Sestamibi Technetium-99m in
diagnosis and follow-up of MM or prediction of disease
outcome. To date there is no head-to-head comparison
between WB-MRI and MIBI scans in MM.
This study aims to determine whether: (1) In simultan-
eous WB-MRI and MIBI scans in the same patients, do
both scans produce the same estimate of disease load
and location (intermodality reliability), or does one of
the scans suggests more extensive disease than the other.
(2) Is there a greater association between the estimate of
the extent of bone disease in one or other of the scans
and the likelihood of death?
SUBJECTS AND METHODS
This study was conducted at the Launceston General
Hospital, a tertiary referral centre for Northern Tasmania,
Australia and was approved by the state-wide Human
Ethics Committee of Tasmania. Informed consent was
obtained from all participants in accordance with the
Declaration of Helsinki. The study was registered
prospectively at the Australia and New Zealand Clinical
Trial Registry web site under registration No:
ACTRN12609000761268 and in the NHS-UK website:
http://www.nhs.uk/Conditions/MRI-scan/Pages/clinical-
trial-details.aspx?TrialId=ACTRN12609000761268.
There were 62 consecutive patients with a median age
of 62 years (range 37–88) and a male-to-female ratio of
ARTICLE SUMMARY
Strengths and limitations of this study
▪ The study was performed prospectively in 62 consecutive MM
patients.
▪ The two scan modalities were performed within 2 days of each
other and were assessed uniformly by expert radiologists and
nuclear medicine physicians in order to minimise possible bias.
▪ This is considered as the first study with head-to-head com-
parison between both modalities, and can therefore be used as
a basis for larger studies.
▪ It was assumed that the MRI and the MIBI scan scoring scales
were measuring the same disease properties. This, however,
may have introduced an unknown degree of imprecision in our
estimates.
▪ The studied group represents a heterogeneous group of
myeloma patients. In theory, different treatments and lytic
lesions may be detected by one method over the other due to
the potential different sensitivity between both imaging modal-
ities. However, this was not addressed by the current study
and may require further investigation.
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33 : 29 recruited at a single centre. Median duration of
follow-up was 16.8 months (maximum 24 months),
during which 13 of 62 patients succumbed. Most of the
patients had IgG (35 patients) myeloma while 15
patients had IgA myeloma, four patients had smoulder-
ing myeloma and the remaining eight patients had light
chain myeloma. The WHO criteria were used for the
diagnosis of MM.18
A standard therapy with dexamethasone and thalido-
mide was applied in most of the cases (table 1).
Second-line treatment was started after failing to achieve
at least a minimal response with the first treatment
defined by disease progression of 25% in serum M
protein (at least 5 g/l) or urinary Bence Jones protein
(at least 200 mg/day), or 50% increase of serum free
light chain level, or 10% increase of marrow plasmacyto-
sis, or increase of the number of lytic lesions, or the
presence of hypercalcaemia (corrected serum calcium
>2.65 mmol/l), or finally in case of non-toleration to the
first-line treatment. The salvage therapy include lenali-
domide (12) or bortezomib (8), determined by disease
stage and toleration of treatment. Ten patients under-
went bone marrow transplantation.
Diagnostic management
Once enrolled in the trial, the participants underwent a
MIBI scan and a WB-MRI. The vast majority of patients
had both scans on the same day and all of them were
performed within 48 h of each other with the MRI scan
performed first. This was to avoid any possible effect of
the Sestamibi Technetium-99m injection on the MRI
scan results. The scans were interpreted by two inde-
pendent consultant radiologists and nuclear medicine
physicians with greater than 15 years of experience. The
results were converted into a spreadsheet format where
the body was represented as 61 bone compartments for
statistical analysis. The same radiologists and nuclear
medicine physicians were used to interpret all the scans
Table 1 Patient characteristics




Median age 62 years (range, 37–88)
<60 years 16
>60 years 46













Higher staging after MRI scan compared to skeletal survey 14





Lenalidomide second-line therapy 12/57
Bortezomib second-line therapy 8/57
No treatment 3/62
Bone marrow transplantation salvage therapy 10/57
Cytogenetic risk stratification
Normal karyotype 36
Complex cytogenetic with >5 abnormalities 11
Complex cytogenetic including chromosome 13 abnormality 4
Abnormal karyotype with less than 5 cytogenetic abnormalities 5
Insufficient marrow cells or unable to grow bone marrow culture 6
MIBI, Sestamibi Technetium-99m-bone marrow.
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using the same special format. Standardised protocols
and assessments were used for both MRI and MIBI
scans.
MRI protocol
The same machine was used for all the MRIs performed—
an Avanto 1.5T system from Siemens Medical Solutions. A
similar protocol to Baur-Melnyk et al8 was employed with
some modifications. The patients were placed head-first in
the supine position. Head, neck, body-matrix and periph-
eral coils were utilised. For the examination of the spine,
T1-weighted turbo spin-echo (TR/TE 584/10 for upper
and 520/11 for lower, field of view 350 mm upper 380 mm
lower, slice thickness 3 mm upper, 3.5 mm lower) and
turbo spin echo short tau inversion recovery (STIR; TR/
TE/T1 5000/51/180, field of view 350 mm upper,
380 mm lower, slice thickness 3 mm upper 3.5 mm lower)
were performed in the sagittal plane.
The base of skull and vertex were imaged in the axial
plane with T1-weighted spin-echo (TR/TE 575/11, field
of view 230 mm, slice thickness 5 mm) and turbo spin
echo STIR (TR/TE/T1 6980/11/180). The sternum
and posterior ribs were imaged in the coronal plane
with T1-weighted turbo spin echo (TR/TE 596/7.8, field
of view 480 mm, thickness of slice 5 mm) and turbo spin
echo STIR (TR/TE/T1 7490/100/170). However, the
ribs are too small for their internal marrow signal to be
confidently interpreted, especially on T1 images, unless
they are obviously destroyed or if there is a large lesion
arising from the ribs. The pelvis was imaged in the
coronal plane with T1-weighted turbo spin echo (TR/
TE 682/11, field of view 480 mm and slice thickness
5 mm) and turbo spin echo STIR (TR/TE 4200/87/
170). The lower limbs down to the mid-shin of the tibia
were imaged in the coronal plane spin with T1-weighted
turbo spin echo (TR/TE 504/11, field of view 480 mm,
slice thickness 5 mm) and turbo spin echo STIR (TR/
TE/T1 3850/87/170). The mean time for each scan to
occur was 50 min.
Sestamibi bone marrow scan protocol
The same dose of MIBI—30 mCi (1110 MBq)—was used
for each patient. Prior to intravenous injection, each
patient was rested on the bed for at least 20 min.
Imaging started at 5 min postinjection with a wide
field of view γ-camera equipped with a low-energy high-
resolution collimator. The WB scan proceeded at
30 cm/min. When completed, lateral femora images
were taken with each view, took approximately 2 min
and, if required, a single positron emission CT was
performed.
Outcome measures
The extent of bone MM as interpreted using the MRI
scans was classified anatomically as focal or diffuse and
then, according to intensity of the lesion, to high, inter-
mediate and low. The extent of bone marrow MIBI
uptake was scored accordingly. Morphology was classed
as normal, diffuse, focal or micronodular. Severity was
graded as low (<20% infiltration), intermediate
(20–50% infiltration) or high (>50% infiltration), and
the severity scale was applied only to the focal morph-
ology. The severity and grade of positive diagnostic
imaging reports were treated as a single rank order
scale: 0=no lesions; 1=low-density focal; 2=intermediate-
density focal; 3=high-density focal; 4=focal diffuse;
5=diffuse. The posterior ribs could not be imaged in the
MRI scan, but the sternum could be imaged. Thus, the
results for 25 ribcage bones in each patient (12 ribs by 2
sides plus sternum) were available for the MIBI and
MRI-STIR scans, and one ribcage bone result (sternum
only) was available for the MRI-T1 scan.
In a number of the result scale versus scan categories,
no patient existed in that condition, or there was no
death in a patient with that condition. In order to allow
analysis of mortality data: (1) the no detection and low-
intensity focal disease categories were combined and (2)
the focal diffuse and diffuse categories were combined.
The mortality status of the patients in January 2012 was
determined using the Australian National Death
Register to avoid distress to relatives caused by sending
communications to patients who have died.
Statistical analysis
Concordance between MIBI and WB-MRI (either axial
plane with T1 or turbo spin echo STIR) was tested by cal-
culation of the kappa statistic for inter-rater agreement,
expressed as observed and expected agreement (expected
agreement is based on the random distribution of diagnos-
tic results); κ value (range −1.00 to 0 to 1.00 indicating
high discordance to no concordance to full concordance,
respectively); and p value. The number of positive results
reported from the three scan modalities for each bone
group (using the scan scale score for each scan as the
outcome variable and the scan method as the predictor
variable) were compared in the same patients at the same
time using repeated-measures ordered logistic regression
(a non-parametric equivalent of general linear modelling;
with results expressed as OR with 95% CIs and p values).
Adjustment for age, gender and time from diagnosis did
not alter the OR estimates, so no adjusted results are
reported for this analysis. Each group of bones was
assessed separately, but the readings from all the bone
compartments in each group were pooled. The association
between time in months from the scan performance to
death or censoring date of 1 January 2012 and the severity
and grade of positive diagnostic results was compared
using repeated-measures Cox proportional hazards regres-
sion (HR; 95% CIs; p values), adjusted for age and gender,
time from diagnosis to imaging scans, clinical stage,
number of lines of treatment, M-component and cytogen-
etic abnormalities. This was done using simultaneous
interaction analysis with inclusion of each of the results of
the three imaging modalities in the models, in order to
determine which imaging modality most closely predicted
mortality under the clinical management given to the
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patients. Results were corrected for multiple comparisons
which were appropriate using the Holm method. All ana-
lyses were performed using Stata SE12.0 for Windows
(StataCorp, College Station, Texas, USA).
RESULTS
We have analysed both scan results according to bone
compartments. Furthermore, we have entered the
results of MRI scan images in two different categories
according to image type as MRI-T1 (axial plane with T1)
or MRI-STIR (turbo spin echo STIR). In detecting skull
lytic lesions, there were no significant differences
between the scans; however, there was a tendency for
MRI scan to detect more MM lesions than MIBI scan
(p=0.09). Nevertheless, for vertebral lytic disease (cer-
vical, thoracic and lumbar), both MRI-T1 and MRI-STIR
detected more disease than MIBI scan (p<0.001). There
was no statistical difference between both MRI techni-
ques in detecting myeloma bone disease in the spine. In
the pelvis, MRI-T1 detected significantly more disease
than MIBI scan (p=0.03) while there is no statistical dif-
ference between MRI-STIR and MIBI scan. In the long
bones (femur, humerus, clavicle and scapula), MRI-T1
detected less disease than MIBI scan (p<0.001), while
there were no significant differences noted between
both MRI-STIR and MIBI scans. In the ribcage, the
MRI-T1 imaged the sternum but was not technically able
to detect the myeloma involvement of the ribs, while the
MIBI scan showed a significant ability in detecting lytic
lesion of the ribs over MRI-STIR scan (p<0.001).
Thirteen of the 62 patients died during the 24-month
follow-up period, all from progression of MM. When the
association between scan result and death rate secondary to
disease progression (as measured by HR) was examined
(figure 1), a clear step-wise increase in likelihood of death
was seen for the MIBI scan for all bone compartments
taken together, while the association was more irregular for
the MRI scans (tables 2 and 3). This trend was seen in the
combined all compartments analysis (MRI-T1 vs MIBI
p=0.019; MRI-STIR vs MIBI p=0.047), the ribcage (MRI-T1
vs MIBI p=0.011; MRI-STIR vs MIBI p=0.004), but was par-
ticularly strongly seen in the thoracic vertebrae (MRI-T1 vs
MIBI p<0.001; MRI-STIR vs MIBI p=0.001). This pattern
was less discernible in the skull, pelvis, long bones and cer-
vical and lumbar vertebrae (figure 2). When adjusted for
other prognostic indicators, in all bones combined, the
mean MIBI scan result provides a better prediction of mor-
tality than the mean result from the MRI scans (MRI_T1 vs
MIBI HR for trend 0.70; 95% CI 0.53 to 0.92; p=0.019: and
MRI-STIR vs MIBI HR for trend 0.80; 95% CI 0.64 to 1.00;
p=0.044) when patients receive standard therapy for
myeloma (table 3). If the combined thoracic vertebrae and
ribcage bones are examined in isolation, the MIBI results
provide a good prediction of mortality over 24 months
(mean result per bone group HR for trend 2.58; 95% CI
1.73 to 3.86; p<0.001), while the MRI scan results compared
with MIBI had lower levels of prediction (MRI-T1 mean
result per bone group HR for trend 1.11; difference from
MIBI 0.43; 95% CI 0.27 to 0.67; p<0.001: MRI-STIR mean
result per bone group HR for trend 1.14; difference from
MIBI 0.44; 95% CI 0.30 to 0.66; p<0.001). However, this
bone grouping was not part of a prior hypothesis. Possible
Figure 1 Prediction of death due to disease progression by
types of lesions in different imaging methods. In the 62
myeloma patients, the upper graph represents sestamibi bone
marrow scan, middle graph; whole body MRI-T1 scan and the
lower graph represents the STIR version of MRI scan.
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covariate associations with death rate were calculated for
age (HR 3.88; 95% CI 0.95–15.9; p=0.06), gender (HR 2.69;
95% CI 0.41 to 17.6; p=0.3), time from diagnosis to scan
prior to follow-up period (HR 3.38; 95% CI 0.62 to 18.4;
p=0.16), presence of five or more cytogenetic abnormalities
(HR 2.49; 95% CI 0.77 to 8.02; p=0.13) and lines of treat-
ment (HR 1.44; 95% CI 0.91 to 2.28; p=0.12).
Cost-effectiveness analysis
There is no cost item for WB-MRI scan at present in the
benefit scheme of Medicare Australia; however, based on
approximate costs of skull MRI ($403.20), pelvic MRI
($403.20) and Spine MRI ($358), the total costs would
be about $1164.4 while MIBI scan cost is $489.7.
Nevertheless, a full body MRI scan may cost less than
combining different body parts as it is less labour inten-
sive and time consuming. At the time of analysis $1
AUD is equal to $1 USD.
DISCUSSION
The true gold standard for myeloma disease detection
would be bone marrow biopsy with histological, molecular
biological and histochemical examination of the biopsy
specimens in a laboratory where disease prognosis will be
determined by the acquired genetic changes in the bone
marrow cells and the resulting proliferation and location
defects. This is obviously not feasible, since the relevant
Table 2 Estimates of concordance of grading* of results of MIBI, MRI and STIR scans in patients with multiple myeloma,
and the relative frequency of different positive results
Concordance† Comparison of frequency‡
Agreement (%)
Expected
agreement (%) kappa p Value OR 95% CI p Value
Skull (N=61; % positive 27.9%)
MRI-T1 vs MIBI 73.8 68.7 0.162 0.007 2.05 (0.90 to 4.63) 0.09
MRI-STIR vs MIBI 75.4 67.7 0.239 0.001 2.08 (1.00 to 4.33) 0.10
MRI-STIR vs MRI-T1 85.3 61.8 0.614 <0.001 1.02 (0.61 to 1.70) 0.95
Cervical vertebrae (N=434; % positive 34.3%)
MRI-T1 vs MIBI 65.7 62.8 0.076 <0.001 7.26 (5.11 to 10.3) <0.001
MRI-STIR vs MIBI 61.8 59.9 0.046 0.004 8.13 (5.66 to 11.7) <0.001
MRI-STIR vs MRI-T1 74.7 46.6 0.526 <0.001 1.12 (0.94 to 1.34) 0.21
Thoracic vertebrae (N=744; % positive 50.7%)
MRI-T1 vs MIBI 53.4 41.5 0.203 <0.001 1.65 (1.43 to 1.91) <0.001
MRI-STIR vs MIBI 49.5 39.5 0.165 <0.001 1.87 (1.60 to 2.19) <0.001
MRI-STIR vs MRI-T1 71.5 39.8 0.527 <0.001 1.13 (0.98 to 1.31) 0.10
Lumbar vertebrae (N=310; % positive 51.6%)
MRI-T1 vs MIBI 55.5 39.4 0.266 <0.001 1.77 (1.45 to 2.16) <0.001
MRI-STIR vs MIBI 51.9 40.3 0.195 <0.001 1.58 (1.26 to 2.00) <0.001
MRI-STIR vs MRI-T1 76.8 38.0 0.626 <0.001 0.90 (0.75 to 1.08) 0.25
Pelvis (N=183; % positive 60.7%)
MRI-T1 vs MIBI 48.6 32.0 0.245 <0.001 1.37 (1.06 to 1.78) 0.032
MRI-STIR vs MIBI 53.0 36.1 0.265 <0.001 0.85 (0.66 to 1.10) 0.21
MRI-STIR vs MRI-T1 68.9 33.9 0.529 <0.001 0.62 (0.49 to 0.78) <0.001
Long bones (femur, humerus, scapular and clavicles) (N=343; % positive 30.0%)
MRI-T1 vs MIBI 76.7 62.8 0.374 <0.001 0.62 (0.49 to 0.80) <0.001
MRI-STIR vs MIBI 65.9 55.3 0.236 <0.001 1.23 (0.93 to 1.62) 0.15
MRI-STIR vs MRI-T1 78.4 61.3 0.443 <0.001 1.97 (1.49 to 2.60) <0.001
Ribcage§ (MRI vs MIBI and MRI vs STIR: N=54; % positive 55.6%) (STIR vs MIBI: N=1,159; % positive 39.2%)
MRI-T1 vs MIBI 55.6 35.4 0.313 <0.001 1.02 (0.61 to 1.72) >0.90
MRI-STIR vs MIBI 46.3 32.9 0.200 0.001 3.26 (1.93 to 5.51) <0.001
MRI-STIR vs MRI-T1 70.4 39.6% 0.510 <0.001 1.29 (0.79 to 2.11) 0.62
*Grading of diagnostic results of the bone scan, MRI and STIR scans were: 0, no abnormality; 1, focal low intensity; 2, focal intermediate;
3, focal high; 4, diffuse focal or micronodular; 5, diffuse. N is number of patients multiplied by number of bones where duplicate simultaneous
scans were available; % positive is the percentage of bones where any of the scans were positive at any grade.
†Concordances between results of the MIBI scan, MRI and STIR scans, estimated by inter-rater kappa statistic (range 0 to 1.00 indicating
high discordance to full concordance respectively; this statistic does not distinguish the direction of the disagreement; expected agreement is
based on random distribution of diagnostic results).
‡Comparison of frequency and grade of positive detections of tumour masses by the MRI and STIR scans compared to that in the bone
scans: estimated by unadjusted ordered logistic regression (assuming that higher grades indicate greater tumour masses), expressed as OR;
95% CIs; p values) with p values corrected for multiple comparisons by the Holm method.
§No result was recorded for any of the ribs in the MRI axial plane with T1 scans in any patient. The ribcage included the sternum, which was
imaged by the T1 scans.
MIBI, Sestamibi Technetium-99m-bone marrow; STIR, short tau inversion recovery.
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bones may be inaccessible, and the biopsy process would
be destructive and unacceptable to patients and treating
physicians.
Here, the clinicians are forced to apply indirect scan-
ning methods, which involve transmission or emission of
various radiations (x-ray, CT, MRI or nuclear medicine
scans). These depend not on the absolute properties of
the abnormal cells that directly control the disease severity,
but on the relative absorption/transmission of the radi-
ation compared with the non-diseased tissue. Therefore,
each method will have its own rate of false-positive and
false-negative results. Nonetheless, because none of these
modalities has been validated against the true measure of
the disease, those rates are unknown. However, as an indir-
ect measure of this gold standard, the disease progression
experience of the patients is used as a proxy for disease
severity.
There are a number of positive findings which have
emerged from our study. As a direct comparison
between both MIBI and WB-MRI scans in diagnosis of
bone disease of MM, it seems that the MRI scan
identifies more MM bone disease than the MIBI scan
with more sensitivity in detecting myelomatous deposits
in the spine and to a lesser extent in the pelvis and long
bones. In the ribcage, MIBI scan detected more disease
compared with MRI scan (p<0.001), noting that the
MRI scan of the ribcage is technically more difficult due
to patient movement including breathing. Comparison
between axial T1-weighted and STIR sequences shows
that the former is more sensitive in detecting myeloma-
tous disease in the vertebrae than STIR imaging. This is
largely because the lesions are predominantly of inter-
mediate and low signal at both T1-weighted and STIR
imaging, and are better outlined and contrasted when
marrow fat signal is preserved, as in T1-weighted
imaging. The STIR sequence selectively suppresses the
signal from fatty marrow in the spine, reducing lesion
contrast and detection sensitivity (figure 3). Lesions that
are of intermediate or low signal at T1-weighted MRI
and high signal at STIR MRI are in the minority. Our
analysis compares the results of the three scans (two
interpretations of an MRI scan and an MIBI scan) for
Table 3 Disease progression risk with subsequent mortality in association with positive bone marrow scan (MIBI) or MRI
results
Result*
Mean result in each bone group†
Total Died HR‡ 95% CI p Value
MIBI 0 32 1 1.00
1 16 4 2.50 (1.18 to 5.30) 0.05
2 11 6 4.17 (1.60 to 10.9) 0.014
3 3 2 6.27 (2.22 to 17.7) 0.003
4
5
Absolute trend 1.51 (1.20 to 1.91) 0.001
Trend relative to MIBI 1.00
MRI-T1 0 29 2 1.33 (0.92 to 1.93) 0.13
1 10 3 2.20 (0.29 to 16.8) >0.90
2 4 2 1.10 (0.05 to 25.9) 0.83
3 10 4 2.48 (0.33 to 18.6) >0.90
4 8 2 1.88 (0.11 to 33.5) >0.90
5 1 0
Absolute trend 1.06 (0.83 to 1.35) 0.44
Trend relative to MIBI 0.70 (0.53 to 0.92) 0.019
MRI-STIR 0 23 1 1.01 (0.64 to 1.59) >0.90
1 16 3 1.61 (0.18 to 14.7) 0.006
2 5 3 2.34 (0.13 to 41.6) 0.13
3 7 2 4.37 (0.46 to 41.7) 0.004
4 10 4 2.32 (0.15 to 36.1) <0.001
5 1 0
Absolute trend 1.20 (1.01 to 1.44) 0.044
Trend relative to MIBI 0.80 (0.64 to 1.00) 0.047
*Results of investigation: None, no lesion; 1, focal (low density); 2, focal (intermediate); 3, focal (high); 4, diffuse focal; 5, diffuse.
†The mean result for each bone group was taken as the predictor of disease progression.
‡Association between result score of imaging modality: relative risk as HR (95% CIs; p value) was estimated using repeated-measures Cox
proportional hazards regression, adjusted for age, gender, time from diagnosis to imaging scans, clinical stage, number of lines of treatment,
M-component and cytogenetic abnormalities; p values corrected for multiple comparisons by the Holm method. Each result score value was
first treated as a categorical variable, and then as a continuous variable to estimate the linear trends: the trend for each modality was
expressed as an absolute effect, and then the trends of the two MRI modalities were expressed as relative effects compared with the MIBI
trend.
MIBI, Sestamibi Technetium-99m-bone marrow; STIR, short tau inversion recovery.
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each patient, and then sums those comparisons across
the entire patient group. Since each patient has the
same age, gender and time from diagnosis for that
internal comparison, those covariates will have no effect
on the intrasubject comparison. Unless there is a system-
atic strong effect on the difference between the scans
(which was not seen), the estimates of the difference
across the group will not be changed. The pattern of
prognostic prediction differs from the degree of identifi-
cation of MM bone lesions suggesting that the nuclear
medicine MIBI scan provides a better prediction of
disease mortality than either of the MRI sequences
(MRI-T1 vs MIBI p=0.19; MRI-STIR vs MIBI p=0.047).
This may suggest that some MRI-detected lesions are of
lesser significance than those imaged by the MIBI scan.
This is intuitively unsurprising for at least two possible
reasons: (1) not all lesions that are of intermediate or
low signal on T1-weighted and STIR imaging represent
myelomatous deposits; and (2) myeloma deposits that
are clinically quiescent may appear morphologically
similar to those that progress. It is worth noting that
both MIBI scan and WB-MRI scans performed better
than conventional skeletal plain x-ray survey as 15
patients and 14 patients, respectively, had a higher clin-
ical staging according to both scans compared with rou-
tinely performed x-ray examination (table 1).
Several trials compared WB-MRI scan versus CT scan
and showed superior results favouring the MRI
scan.7 8 10 However, no correlation has been made in
the prediction of overall disease outcome or death rate
as our study suggests. On the other hand, one study
showed that MIBI scan detects additional MM sites com-
pared with skeletal survey in 38 of 56 studied patients
(68%). This is considered superior to FDG-PET scan
that detects 50% of additional sites for MM over skeletal
survey.19
Our study has a few shortcomings. First, the two scales
of assessment of severity of MM bone involvement
(none, focal, focal-diffuse and diffuse) and signal
density (low, intermediate and high, applied only to
focal morphology) were assumed to be able to be con-
verted into a single sequential scale, that is, positively
associated with tumour mass in order to simplify the
analysis. It was also assumed that the MRI and the MIBI
scan scoring scales were measuring the same disease
properties. This, however, may have introduced an
unknown degree of imprecision in our estimates.
Second, all the patients were receiving standard chemo-
therapy for myeloma, and tumour infiltration that can
be detected by one technique may be influenced by
certain therapy compared with a tumour that can be
detected by the other imaging modality.
In summary, MIBI scan obtains an image of all import-
ant bone compartments in the body in one single exam-
ination, and is less time consuming and more
comfortable for the patient than MRI. Although there is
a mild-to-moderate degree of intermodality reliability
between the different imaging techniques, the two MRI
modalities appear to report higher grades of bone
lesions than the MIBI scan. Moreover, our study suggests
that mortality is better predicted by components of the
MIBI scan, although this observation would need to be
Figure 2 Association between
result score of imaging modality:
relative risk as HR (95% CIs;
p value) was estimated using Cox
proportional hazards regression,
adjusted for age, gender and time
from diagnosis to imaging scans;
p values corrected for multiple
comparisons by the Holm
method. Each result score value
was treated as a continuous
variable to estimate the linear
trends in mortality: the absolute
trend for each modality was
estimated (shown as symbol and
error bars), and then the relative
trends of the two MRI modalities
were compared to the MIBI scan
trend (shown as p values only).
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confirmed in other studies. The greater apparent lesion
detection and poorer prognostic performance of MRI
scans may occur either through imaging of malignant
tissue that has been possibly affected by chemotherapy,
or through imaging of tissue reactions that have little
prognostic significance. Alternatively, the MRI scans may
be more sensitive to early disease than MIBI scans and
that early disease may manifest itself at a date beyond
our short window of observation. Our data suggest that
it is beneficial to employ the new technology with
WB-MRI and MIBI scans in prediction of myeloma
disease progression as well as outcome. Further trials will
be required to confirm the utility of these different
imaging modalities.
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